SAB Biotherapeutics (SABS) Cash from Financing Activities (2020 - 2026)

SAB Biotherapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at $89.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 51783.26% year-over-year to $89.9 million; the trailing twelve-month figure through Mar 2026 stood at $258.4 million (up 27236.78% YoY), and the FY2025 full-year result was $168.3 million, up 14452.36% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $89.9 million, up from -$41685.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $168.7 million in Q3 2025, with the low at -$6.3 million in Q1 2022.
• Historically, Cash from Financing Activities has averaged $19.1 million across 5 years, with a median of -$173985.0 in 2025.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 13794.46% — and 2026, when it jumped 51783.26%.
• SAB Biotherapeutics' Cash from Financing Activities stood at $8.4 million in 2022, then jumped by 706.4% to $67.6 million in 2023, then tumbled by 99.68% to $216961.0 in 2024, then slumped by 119.21% to -$41685.0 in 2025, then soared by 215815.78% to $89.9 million in 2026.
• The last three Cash from Financing Activities figures came in at $89.9 million (Q1 2026), -$41685.0 (Q4 2025), and $168.7 million (Q3 2025), per Business Quant data.